Trexquant Investment LP Affimed N.V. Transaction History

Trexquant Investment LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $204,086 - $312,490	-55,308 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $297,003 - $391,027	55,308 New	55,308 $305,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $335,530 - $454,843	-60,565 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$7.78 - $11.4 $192,142 - $281,545	24,697 Added 68.86%	60,565 $515,000
Q1 2021 May 13, 2021	SELL	$5.12 - $8.48 $42,997 - $71,215	-8,398 Reduced 18.97%	35,868 $284,000
Q4 2020 Feb 11, 2021	BUY	$3.16 - $7.03 $139,880 - $311,189	44,266 New	44,266 $258,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.